More than 12,000 interventional cardiologists, nurse, technicians, scientists and industry innovators from around the world will meet to share the latest research, developments and best practice in treating cardiovascular conditions, including coronary and valvular heart disease and stroke, with minimally invasive techniques.
New research highlights
- New efficacy and safety results from the LEADERS FREE ACS study, comparing a polymer-free umirolimus-coated stent with a bare metal stent in a prespecified sub-study of patients with acute coronary syndrome (ACS). (Late Breaking trials, registries and innovations, Tuesday, 17 May 11:20 - 12:20 Main Arena - presented by Christoph Naber at 11:20)
- A first look at the long-term durability of transcatheter heart valves, with data on long-term follow-up for up to 10 years. (Late Breaking trials, registries and innovations, Tuesday, 17 May 11:20 -- 12:20 Main Arena -- presented by Dany Dvir at 11:56)
- One-year results from the OPINION study: how does optical frequency domain imaging (OFDI) compare with intravascular ultrasound (IVUS) for assessing lesion morphology during percutaneous coronary intervention (PCI) in clinical outcomes? (Late Breaking trials, registries and innovations, Tuesday, 17 May 11:20 - 12:20 Main Arena - presented by Takashi Kubo at 11:32)
Sharing expertiseEuroPCR provides a unique experience for participants to observe and discuss live cases in which world-leading experts demonstrate cardiovascular interventions from their own cath labs at 12 state-of-the-art centres in nine countries around the world, including China, France, Germany, Israel, Italy, Singapore, Switzerland, the United Arab Emirates and the UK. At EuroPCR 2016 there will be more than 50 hours of live demonstrations, including:
- Interventions for valvular disease and heart failure, such as transcutaneous aortic valve implantation (TAVI) and edge-to-edge mitral repair
- Coronary interventions, including a left main percutaneous coronary intervention (PCI) and PCI of complex bifurcation
- Interventions for hypertension and stroke, with cases including carotid stenting and left atrial appendage closure
- Peripheral interventions, such as percutaneous treatment of abdominal aortic aneurysm.
Help for journalists to cover EuroPCR 2016
For any press-related inquiries, please contact:EuroPCR Press Coordinator, Isabelle Uzielli email@example.com
Register and attend EuroPCR 2016 as a journalist
Press registration for EuroPCR is open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to http://www.
EuroPCR press releases
EuroPCR press releases can be found at http://www.
Attend press briefings
For the press briefing schedule check http://www.
Notes to Editors
What is EuroPCR?
EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 12,000 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Istanbul Turkey, Chengdu China and Tokyo Japan.
For further information on EuroPCR, AsiaPCR/SingLIVE, PCR London Valves, GulfPCR-GIM, AfricaPCR, PCR Istanbul Peripheral, PCR-CIT China Chengdu Valves, PCR Tokyo Valves & PCR, please contact: Anne-Sophie Lartigau at firstname.lastname@example.org.
For more information, please visit http://www.